

=> d 117 1-21

L17 ANSWER 1 OF 21 USPATFULL  
AN 1999:155183 USPATFULL  
TI Methods of using genetically engineered cells that produce  
**insulin** in response to glucose  
IN Newgard, Christopher R, Dallas, TX, United States  
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)  
PI US 5993799 19991130  
AI US 1995-452334 19950526 (8)  
RLI Division of Ser. No. US 1994-312120, filed on 26 Sep 1994, now patented,  
Pat. No. US 5811266 which is a division of Ser. No. US 1994-162044, filed on 23 Jun 1994, now patented, Pat. No. US 5744327 which is a continuation-in-part of Ser. No. US 1992-819326, filed on 13 Jan 1992, now patented, Pat. No. US 5427940 which is a continuation-in-part of Ser. No. US 1991-710038, filed on 3 Jun 1991, now abandoned And a continuation-in-part of Ser. No. US 1990-483224, filed on 20 Feb 1990, now patented, Pat. No. US 5175085  
PRAI WO 1991-US9204737 19910602  
DT Utility  
LN.CNT 2864  
INCL INCLM: 424/093.210  
INCLS: 435/006.000; 435/320.100; 435/325.000; 435/455.000  
IC [6]  
ICM: A01N063-00  
EXF 210/192; 210/310; 435/240.2; 435/325; 435/455; 435/172.3; 435/320.1; 435/69.1; 435/6; 935/57; 935/62; 935/71; 421/93.21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 2 OF 21 USPATFULL  
AN 1999:96338 USPATFULL  
TI Method of treating **insulin resistance**  
IN Broderick, Carol Lynn, Monrovia, IN, United States  
DiMarchi, Richard Dennis, Carmel, IN, United States  
Heiman, Mark Louis, Indianapolis, IN, United States  
Stramm, Lawrence Edward, Indianapolis, IN, United States (U.S. corporation)  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)  
PI US 5939387 19990817  
AI US 1996-708620 19960905 (8)  
PRAI US 1995-3473 19950908 (60)  
DT Utility  
LN.CNT 693  
INCL INCLM: 514/012.000  
INCLS: 424/130.100; 530/300.000  
NCL NCLM: 514/012.000  
NCLS: 424/130.100; 530/300.000  
IC [6]  
ICM: A61K038-00  
ICS: A61K039-395  
EXF 514/12; 424/130.1; 530/300  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

GHRH  
agent

L17 ANSWER 3 OF 21 USPATFULL

AN 1999:78775 USPATFULL  
TI Compounds with growth hormone releasing properties  
IN Peschke, Bernd, M.ang.l.o slashed.v, Denmark  
Ankersen, Michael, Frederiksberg, Denmark  
Hansen, Thomas Kruse, Herlev, Denmark  
Th.o slashed.gersen, Henning, Farum, Denmark  
PA Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)  
PI US 5922770 19990713  
AI US 1997-896550 19970717 (8)  
PRAI DK 1996-803 19960722  
DT Utility  
LN.CNT 4041  
INCL INCLM: 514/619.000  
INCLS: 514/255.000; 514/307.000; 514/319.000; 514/400.000; 514/419.000;  
514/428.000; 514/438.000; 514/443.000; 544/400.000; 546/146.000;  
546/205.000; 548/338.100; 548/495.000; 548/567.000; 548/568.000;  
549/058.000; 549/076.000; 564/157.000  
NCL NCLM: 514/619.000  
NCLS: 514/255.000; 514/307.000; 514/319.000; 514/400.000; 514/419.000;  
514/428.000; 514/438.000; 514/443.000; 544/400.000; 546/146.000;  
546/205.000; 548/338.100; 548/495.000; 548/567.000; 548/568.000;  
549/058.000; 549/076.000; 564/157.000  
IC [6]  
ICM: A61K031-165  
ICS: C07C233-11; C07C235-34; C07C237-22  
EXF 546/205; 514/319; 514/619; 564/157  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 21 USPATFULL  
AN 1999:78683 USPATFULL  
TI Methods for treating diabetes  
IN Stephens, Thomas Wesley, Indianapolis, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 5922678 19990713  
AI US 1998-47243 19980324 (9)  
RLI Division of Ser. No. US 1996-678369, filed on 28 Jun 1996, now  
patented,  
Pat. No. US 5756461 *Leptin*  
DT Utility  
LN.CNT 1409  
INCL INCLM: 514/012.000  
INCLS: 530/324.000; 530/350.000  
NCL NCLM: 514/012.000  
NCLS: 530/324.000; 530/350.000  
IC [6]  
ICM: A61K038-00  
ICS: C07K007-10; C07K007-00  
EXF 514/12; 530/324  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 5 OF 21 USPATFULL  
AN 1999:43465 USPATFULL  
TI Methods and compositions for inhibiting hexokinase  
IN Newgard, Christopher B., Dallas, TX, United States  
Han, He-Ping, Dallas, TX, United States  
Becker, Thomas C., Carrollton, TX, United States  
Wilson, John E., East Lansing, MI, United States  
PA Betagene, Inc., Dallas, TX, United States (U.S. corporation)  
Board of Regents, The University of Texas System, Austin, TX, United  
States (U.S. corporation)  
PI US 5891717 19990406  
AI US 1996-588976 19960119 (8)  
DT Utility  
LN.CNT 5470

INCL INCLM: 435/325.000  
 INCLS: 435/069.100; 435/064.700; 435/194.000; 435/320.100; 435/455.000;  
 435/456.000; 435/458.000; 435/463.000; 536/023.200; 536/023.400;  
 935/013.000; 935/014.000; 935/032.000; 935/057.000; 935/060.000;  
 935/070.000; 935/071.000

NCL NCLM: 435/325.000  
 NCLS: 435/069.100; 435/069.700; 435/194.000; 435/320.100; 435/455.000;  
 435/456.000; 435/458.000; 435/463.000; 536/023.200; 536/023.400

IC [6]  
 ICM: C12N005-10  
 ICS: C12N015-85; C12N015-56; C12N015-62

EXF 435/69.1; 435/69.7; 435/194; 435/172.3; 435/252.3; 435/320.1; 435/325;  
 435/455; 435/456; 435/458; 435/463; 536/23.2; 536/23.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 6 OF 21 USPATFULL  
 AN 1998:162337 USPATFULL  
 TI Hexokinase inhibitors  
 IN Newgard, Christopher B., Dallas, TX, United States  
 Han, He-Ping, Arlington, TX, United States  
 Normington, Karl D., Dallas, TX, United States  
 PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)  
 Betagene, Inc., Dallas, TX, United States (U.S. corporation)

PI US 5854067 19981229  
 AI US 1996-588983 19960119 (8)  
 DT Utility  
 LN.CNT 5377

INCL INCLM: 435/366.000  
 INCLS: 425/004.000; 425/006.000; 425/091.100; 425/091.310; 425/183.000;  
 425/320.100; 425/325.000; 536/023.100; 536/024.310; 536/024.500

NCL NCLM: 435/366.000  
 NCLS: 435/004.000; 435/006.000; 435/091.100; 435/091.310; 435/183.000;  
 435/320.100; 435/325.000; 536/023.100; 536/024.310; 536/024.500

IC [6]  
 ICM: C12N015-85  
 ICS: C12N015-00; C12N015-63; C12Q001-68

EXF 435/325; 435/4; 435/6; 435/69.1; 435/320.1; 435/172.3; 424/94.1;  
 536/23.1; 536/24.5; 514/44; 576/24.31

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 7 OF 21 USPATFULL  
 AN 1998:157111 USPATFULL  
 TI Screening assay for compounds stimulating somatostatin transcription  
 factor -1 binding to an STF-1 binding site  
 IN Montminy, Marc, Wellsley, MA, United States  
 Peers, Bernard, Waremm, Belgium  
 PA Research Development Foundation, Carson City, NV, United States (U.S. corporation)  
 PI US 5849493 19981215  
 AI US 1996-757316 19961127 (8)  
 PRAI US 1995-7722 19951130 (60)  
 DT Utility  
 LN.CNT 1182

INCL INCLM: 435/006.000  
 INCLS: 435/004.000

NCL NCLM: 435/006.000  
 NCLS: 435/004.000

IC [6]  
 ICM: C12Q001-02  
 ICS: C12Q001-68

EXF 435/6; 435/4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 8 OF 21 USPATFULL

AN 1998:115582 USPATFULL  
TI Methods for producing human **insulin**  
IN Newgard, Christopher B., Dallas, TX, United States  
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)  
PI US 5811266 19980922  
AI US 1994-312120 19940926 (8)  
RLI Division of Ser. No. US 1994-162044, filed on 23 Jun 1994 And a continuation-in-part of Ser. No. US 1992-819326, filed on 13 Jan 1992, now patented, Pat. No. US 5427940 which is a continuation-in-part of Ser. No. US 1991-710038, filed on 3 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-483224, filed on 20 Feb 1990, now patented, Pat. No. US 5175085  
DT Utility  
LN.CNT 2823  
INCL INCLM: 435/069.400  
INCLS: 435/069.100; 435/070.100; 435/070.300; 530/303.000  
NCL NCLM: 435/069.400  
NCLS: 435/069.100; 435/070.100; 435/070.300; 530/303.000  
IC [6]  
ICM: C12N015-17  
ICS: C12P021-02  
EXF 435/69.4; 435/69.1; 435/240.2; 435/320.1; 435/71.1; 435/71.2; 435/325; 530/350; 530/303  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 9 OF 21 USPATFULL  
AN 1998:95431 USPATFULL  
TI Methods of preparing genetically engineered cells that produce **insulin** in response to glucose  
IN Newgard, Christopher B., Dallas, TX, United States  
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)  
PI US 5792656 19980811  
AI US 1995-452346 19950526 (8)  
RLI Division of Ser. No. US 1994-312120, filed on 26 Sep 1994 which is a division of Ser. No. US 1994-162044, filed on 23 Jun 1994, now patented,  
Pat. No. US 5744327 which is a continuation-in-part of Ser. No. US 1992-819326, filed on 13 Jan 1992, now patented, Pat. No. US 5427940 which is a continuation-in-part of Ser. No. US 1991-710038, filed on 3 Jun 1991, now abandoned  
DT Utility  
LN.CNT 2905  
INCL INCLM: 435/325.000  
INCLS: 435/172.100; 435/382.000; 435/395.000  
NCL NCLM: 435/325.000  
NCLS: 435/006.000; 435/382.000; 435/395.000  
IC [6]  
ICM: C12N015-85  
EXF 435/172.1-172.3; 435/325; 435/382; 435/395; 935/52  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 10 OF 21 USPATFULL  
AN 1998:72710 USPATFULL  
TI Conformationally constrained backbone cyclized somatostatin analogs  
IN Hornik, Vered, Rebovot, Israel  
Seri-Levy, Alon, Jerusalem, Israel  
Gellerman, Gary, Jerusalem, Israel  
Gilon, Chaim, Jerusalem, Israel  
PA Peptor Limited, Rehovot, Israel (non-U.S. corporation)  
Yissim Research Development Co. of Hebrew University of Jerusalem, Jerusalem, Israel (non-U.S. corporation)  
PI US 5770687 19980623  
AI US 1996-690090 19960731 (8)

RLI Continuation-in-part of Ser. No. US 1995-488159, filed on 7 Jun 1995  
And Ser. No. US 1995-569042, filed on 7 Dec 1995  
DT Utility  
LN.CNT 2534  
INCL INCLM: 530/311.000  
INCLS: 530/317.000; 530/328.000; 514/009.000; 514/011.000; 514/015.000;  
514/016.000  
NCL NCLM: 530/311.000  
NCLS: 530/317.000; 530/328.000  
IC [6]  
ICM: C07K007-64  
ICS: A61K038-04; A61K038-12  
EXF 530/311; 530/317; 514/9; 514/11; 514/15; 514/16  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 11 OF 21 USPATFULL  
AN 1998:57885 USPATFULL  
TI Methods for treating diabetes  
IN Stephens, Thomas Wesley, Indianapolis, IN, United States  
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.  
corporation)  
PI US 5756461 19980526  
AI US 1996-678369 19960628 (8)  
PRAI US 1995-718 19950630 (60)  
DT Utility  
LN.CNT 1282  
INCL INCLM: 514/012.000  
INCLS: 514/866.000; 530/324.000  
NCL NCLM: 514/012.000  
NCLS: 514/866.000; 530/324.000  
IC [6]  
ICM: A61K038-00  
ICS: A61K038-16; C07K014-00  
EXF 514/12; 514/866  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 12 OF 21 USPATFULL  
AN 1998:48243 USPATFULL  
TI Devices comprising genetically engineered .beta.cells  
IN Newgard, Christopher B., Dallas, TX, United States  
PA Board of Regents, The University of Texas System, Austin, TX, United  
States (U.S. corporation)  
PI US 5747325 19980505  
AI US 1995-452667 19950526 (8)  
RLI Continuation of Ser. No. US 1994-312120, filed on 26 Sep 1994 which is  
a division of Ser. No. US 1993-162044, filed on 3 Dec 1993 which is a  
continuation-in-part of Ser. No. US 1992-819326, filed on 13 Jan 1992,  
now patented, Pat. No. US 5427940 which is a continuation-in-part of  
Ser. No. US 1991-710038, filed on 3 Jun 1991, now abandoned  
DT Utility  
LN.CNT 2835  
INCL INCLM: 435/240.200  
INCLS: 455/006.000; 455/069.100; 455/172.100; 455/172.300; 424/520.000;  
424/425.000; 530/350.000; 530/397.000; 530/303.000; 604/897.100  
NCL NCLM: 435/325.000  
NCLS: 424/425.000; 424/520.000; 435/006.000; 435/069.100; 435/372.200;  
530/303.000; 530/350.000; 530/397.000; 604/891.100  
IC [6]  
ICM: C12N015-17  
ICS: C12N005-00; C12N021-04; A61K001-50  
EXF 210/192; 210/310; 435/240; 424/93.21; 424/425; 604/891.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 13 OF 21 USPATFULL  
AN 1998:45069 USPATFULL  
TI Methods for producing insulin in response to non-glucose  
secretagogues  
IN Newgard, Christopher B., Dallas, TX, United States  
PA Board of Regents, The University of Texas System, Austin, TX, United  
States (U.S. corporation)  
PI US 5744327 19980428  
WO 9221979 19921210  
AI US 1994-162044 19940623 (8)  
WO 1992-US4737 19920602  
19940623 PCT 371 date  
19940623 PCT 102(e) date  
RLI Continuation-in-part of Ser. No. US 1992-819326, filed on 13 Jan 1992,  
now patented, Pat. No. US 5427940 which is a continuation-in-part of  
Ser. No. US 1991-710038, filed on 3 Jun 1991, now abandoned which is a  
continuation-in-part of Ser. No. US 1990-483224, filed on 20 Feb 1990,  
now patented, Pat. No. US 5175085  
DT Utility  
LN.CNT 2864  
INCL INCLM: 435/069.400  
INCLS: 435/069.100; 435/070.300  
NCL NCLM: 435/069.400  
NCLS: 435/069.100; 435/070.300  
IC [6]  
ICM: C12P021-02  
ICS: C12N015-00  
EXF 435/41; 435/69.1; 435/69.2; 435/69.4; 435/70.1; 435/70.3; 435/174;  
435/177; 435/240.1; 435/240.2; 435/240.23; 435/240.243; 435/325;  
435/326; 435/375; 435/395; 435/397  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 14 OF 21 USPATFULL  
AN 1998:36608 USPATFULL  
TI Method for modifying, diagnosing and screening for IGF-I sensitive cell  
barriers  
IN Moses, Alan C., 470 Quinobequin Rd., Waban, MA, United States 02168  
Morrow, Linda A., 11 Rice St., Newton, MA, United States 02159  
Flier, Jeffrey S., 14 Sylvan Ave., West Newton, MA, United States  
02165  
PI US 5736400 19980407  
AI US 1996-759264 19961202 (8)  
RLI Continuation of Ser. No. US 1995-436934, filed on 8 May 1995, now  
abandoned which is a division of Ser. No. US 1994-279831, filed on 25  
Jul 1994, now patented, Pat. No. US 5686408 which is a continuation of  
Ser. No. US 1993-8461, filed on 25 Jan 1993, now abandoned  
DT Utility  
LN.CNT 1169  
INCL INCLM: 435/007.210  
INCLS: 514/003.000; 514/002.000; 435/029.000  
NCL NCLM: 435/007.210  
NCLS: 435/029.000; 514/002.000; 514/003.000  
IC [6]  
ICM: G01N032-50  
EXF 435/7.21; 435/325; 435/29; 514/3; 514/2

L17 ANSWER 15 OF 21 USPATFULL  
AN 1998:9492 USPATFULL  
TI Administration of pirenzepine, methyl scopolamine and other muscarinic  
receptor antagonists for treatment of glucose metabolism disorders  
IN Cincotta, Anthony H., Andover, MA, United States  
Meier, Albert H., Baton Rouge, LA, United States  
Wilson, John M., Charlestown, MA, United States  
PA The General Hospital Corporation, Boston, MA, United States (U.S.  
corporation)

The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA, United States (U.S. corporation)

PI US 5712265 19980127  
AI US 1995-458061 19950601 (8)  
RLI Continuation of Ser. No. US 1994-263607, filed on 20 Jun 1994, now patented, Pat. No. US 5668155 which is a continuation-in-part of Ser. No. US 1992-995292, filed on 22 Dec 1992, now patented, Pat. No. US 5585347 which is a continuation-in-part of Ser. No. US 1991-719745, filed on 24 Jun 1991, now patented, Pat. No. US 5344832 which is a continuation-in-part of Ser. No. US 1990-463327, filed on 10 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-192332, filed on 10 May 1988, now abandoned  
DT Utility  
LN.CNT 1382  
INCL INCLM: 514/200.000  
INCLS: 514/218.000; 514/220.000; 514/291.000; 514/454.000; 514/866.000  
NCL NCLM: 510/151.000  
NCLS: 510/152.000; 510/155.000; 510/156.000  
IC [6]  
ICM: A61K031-545  
ICS: A61K031-55; A61K031-44; A61K031-35  
EXF 514/200; 514/218; 514/220; 514/291; 514/454; 514/866  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 16 OF 21 USPATFULL

AN 97:120612 USPATFULL  
TI Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of type II diabetes  
IN Cincotta, Anthony H., Andover, MA, United States  
Meier, Albert H., Baton Rouge, LA, United States  
Wilson, John M., Charlestown, MA, United States  
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)  
The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA, United States (U.S. corporation)

PI US 5700795 19971223  
AI US 1995-458085 19950601 (8)  
RLI Continuation of Ser. No. US 1994-263607, filed on 20 Jun 1994 which is a continuation-in-part of Ser. No. US 1992-995292, filed on 22 Dec 1992, now patented, Pat. No. US 5585347 which is a continuation-in-part of Ser. No. US 1991-719745, filed on 24 Jun 1991, now patented, Pat. No. US 5344832 which is a continuation of Ser. No. US 1990-463327, filed on 10 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-192332, filed on 10 May 1988, now abandoned  
DT Utility  
LN.CNT 1351

INCL INCLM: 514/200.000  
INCLS: 514/218.000; 514/220.000; 514/291.000; 514/454.000; 514/866.000  
NCL NCLM: 514/200.000  
NCLS: 514/218.000; 514/220.000; 514/291.000; 514/454.000; 514/866.000  
IC [6]  
ICM: A61K031-545  
ICS: A61K031-55; A61K031-44; A61K031-35  
EXF 514/200; 514/218; 514/220; 514/291; 514/454; 514/866  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 17 OF 21 USPATFULL

AN 97:104438 USPATFULL  
TI Method for modifying, diagnosing, and screening for IGF-I sensitive cell barrier properties

IN Moses, Alan C., Waban, MA, United States  
Morrow, Linda A., Newton, MA, United States  
Flier, Jeffrey S., West Newton, MA, United States  
PA The Beth Israel Hospital Association, Boston, MA, United States (U.S.  
corporation)  
PI US 5686408 19971111  
AI US 1994-279831 19940725 (8)  
RLI Continuation of Ser. No. US 1993-8461, filed on 25 Jan 1993, now  
abandoned  
DT Utility  
LN.CNT 1203  
INCL INCLM: 514/003.000  
INCLS: 530/303.000  
NCL NCLM: 514/003.000  
NCLS: 530/303.000  
IC [6]  
ICM: A61K038-30  
EXF 514/3; 530/303  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 18 OF 21 USPATFULL  
AN 97:83981 USPATFULL  
TI Administration of pirenzepine, methyl scopolamine and other muscarinic  
receptor antagonists for treatment of lipid metabolism disorders  
IN Cincotta, Anthony H., Andover, MA, United States  
Meier, Albert H., Baton Rouge, LA, United States  
Wilson, John M., Charlestown, MA, United States  
PA The General Hospital Corporation, Boston, MA, United States (U.S.  
corporation)  
The Board of Supervisors of Louisiana State University and Agricultural  
and Mechanical College, Baton Rouge, LA, United States (U.S.  
corporation)  
PI US 5668155 19970916  
AI US 1994-263607 19940620 (8)  
RLI Continuation-in-part of Ser. No. US 1992-995292, filed on 22 Dec 1992,  
now patented, Pat. No. US 5585347 which is a continuation-in-part of  
Ser. No. US 1991-719745, filed on 24 Jun 1991, now patented, Pat. No.  
US  
5344832 which is a continuation-in-part of Ser. No. US 1990-463327,  
filed on 10 Jan 1990, now abandoned which is a continuation-in-part of  
Ser. No. US 1988-192332, filed on 10 May 1988, now abandoned  
DT Utility  
LN.CNT 1289  
INCL INCLM: 514/340.000  
INCLS: 514/271.000; 514/288.000; 514/291.000; 514/824.000  
NCL NCLM: 514/340.000  
NCLS: 514/271.000; 514/288.000; 514/291.000; 514/824.000  
IC [6]  
ICM: A61K031-435  
ICS: A61K031-495; C07D451-00  
EXF 514/271; 514/288; 514/340; 514/824; 514/291  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 19 OF 21 USPATFULL  
AN 97:49617 USPATFULL  
TI Method for modifying, diagnosing, and screening for IGF-I sensitive  
cell  
barrier properties  
IN Moses, Alan C., Waban, MA, United States  
Morrow, Linda A., Newton, MA, United States  
Flier, Jeffrey S., West Newton, MA, United States  
PA The Beth Israel Hospital Association, Boston, MA, United States (U.S.  
corporation)  
PI US 5637567 19970610  
AI US 1995-437796 19950508 (8)

RLI . Division of Ser. No. US 1994-279831, filed on 25 Jul 1994 which is a continuation of Ser. No. US 1993-8461, filed on 25 Jan 1993, now abandoned  
DT Utility  
LN.CNT 1178  
INCL INCLM: 514/012.000  
INCLS: 514/866.000  
NCL NCLM: 514/012.000  
NCLS: 514/866.000  
IC [6]  
ICM: A61K038-30  
EXF 514/12; 514/3; 514/866  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 20 OF 21 USPATFULL  
AN 97:22755 USPATFULL  
TI Method for treating **insulin resistance** with IGF-I  
IN Moses, Alan C., 470 Quinobequin Rd., Waban, MA, United States 02168  
Morrow, Linda A., 11 Rice St., Newton, MA, United States 02159  
Flier, Jeffrey S., 14 Sylvan Ave., West Newton, MA, United States

02165  
PI US 5612312 19970318  
AI US 1995-436633 19950508 (8)  
RLI Division of Ser. No. US 1994-279831, filed on 25 Jul 1994 which is a continuation of Ser. No. US 1993-8461, filed on 25 Jan 1993, now abandoned  
DT Utility  
LN.CNT 1144  
INCL INCLM: 514/012.000  
INCLS: 514/866.000  
NCL NCLM: 514/012.000  
NCLS: 514/866.000  
IC [6]  
ICM: A61K038-30  
EXF 514/3; 514/12; 514/866; 530/303  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 21 OF 21 USPATFULL  
AN 95:58046 USPATFULL  
TI Engineered cells producing **insulin** in response to glucose  
IN Newgard, Christopher B., Dallas, TX, United States  
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)  
PI US 5427940 19950627  
AI US 1992-819326 19920113 (7)  
RLI Continuation-in-part of Ser. No. US 1991-710038, filed on 3 Jun 1991, now abandoned  
DT Utility  
LN.CNT 2375  
INCL INCLM: 435/240.200  
INCLS: 435/004.000; 435/006.000; 435/069.100; 435/172.100; 435/172.200; 435/172.300; 435/320.100; 424/520.000; 530/350.000; 530/397.000; 530/303.000; 530/389.200  
NCL NCLM: 435/366.000  
NCLS: 424/520.000; 435/004.000; 435/006.000; 435/069.100; 435/320.100; 530/303.000; 530/350.000; 530/389.200; 530/397.000  
IC [6]  
ICM: C12N005-00  
ICS: C12N015-00; C12Q001-68; C12P021-06  
EXF 435/4; 435/6; 435/69.1; 435/172.1; 435/172.2; 435/172.3; 435/240.2; 435/320.1; 435/7.21; 424/520; 530/350; 530/351; 530/387; 530/388; 530/397  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 08:44:56 ON 04 JAN 2000)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE' ENTERED AT 08:45:36 ON 04 JAN 2000  
E JOHANSSON G/AU

L1 81 S E3  
L2 45 S E4  
L3 119 S (L1 OR L2) AND (GH OR (GROWTH AND HORMONE))  
L4 31070 S INSULIN AND SENSITIVITY  
L5 13 S L3 AND L4  
L6 44565 S INSULIN AND RESISTANCE  
L7 8 S L5 AND L6  
E MARIN PER/AU  
L8 119 S L3  
L9 8 S L8 AND L7

FILE 'USPATFULL' ENTERED AT 08:55:33 ON 04 JAN 2000

L10 0 S L5 AND L7 AND (ANALOG OR ANALOGUE)  
L11 349 S NIDDM OR (NON ADJ INSULIN ADJ DEPENDENT ADJ DIABETES ADJ  
MAL  
L12 0 S L5 AND L11  
L13 246 S L6 AND L11  
L14 0 S L3 AND L3  
L15 21 S L13 AND GH  
L16 21 S L6 AND L15  
L17 21 S L9 OR L16  
L18 0 S L9 AND L16

1/4/00  
not applicable  
diabetes

=> d 17 1-8

L7 ANSWER 1 OF 8 MEDLINE  
AN 1999369174 MEDLINE  
DN 99369174  
TI **Growth hormone** and the metabolic syndrome.  
AU **Johannsson G**; Bengtsson B A  
CS Research Centre for Endocrinology and Metabolism, Sahlgrenska University  
Hospital, Goteborg, Sweden.  
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, (1999) 22 (5 Suppl) 41-6.  
Ref: 42  
Journal code: IAM. ISSN: 0391-4097.  
CY Italy  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA English  
FS Priority Journals  
EM 199912  
EW 19991202

L7 ANSWER 2 OF 8 MEDLINE  
AN 97216216 MEDLINE  
DN 97216216  
TI **Growth hormone** treatment of abdominally obese men  
reduces abdominal fat mass, improves glucose and lipoprotein metabolism,  
and reduces diastolic blood pressure [see comments].  
CM Comment in: J Clin Endocrinol Metab 1997 Mar;82(3):725-6  
AU **Johannsson G**; Marin P; Lonn L; Ottosson M; Stenlof K; Bjorntorp  
P; Sjostrom L; Bengtsson B A  
CS Research Center for Endocrinology and Metabolism, Sahlgrenska University  
Hospital, Goteborg, Sweden.. Gudmundur.Johannsson@ss.gu.se  
SO JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, (1997 Mar) 82 (3)  
727-34.  
Journal code: HRB. ISSN: 0021-972X.  
CY United States  
DT (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
(RANDOMIZED CONTROLLED TRIAL)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals  
EM 199706

L7 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2000 ACS  
AN 1999:670806 CAPLUS  
TI Use of **growth hormone** for treatment of anatomic and  
physiologic decrements associated with aging  
AU Bengtsson, Bengt-Ake; **Johannsson, Gudmundur**; Isgaard, Jorgen  
CS Research Center for Endocrinology and Metabolism, Sahlgrenska University  
Hospital, Goteborg, Swed.  
SO J. Anti-Aging Med. (1998), 1(3), 197-205  
CODEN: JAMEF8; ISSN: 1094-5458  
PB Mary Ann Liebert, Inc.  
DT Journal  
LA English

L7 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2000 ACS

AN 1997:696651 CAPLUS

DN 127:355665

TI Use of **growth hormone** for treatment of primary  
**insulin resistance** syndrome and abdominal obesity

IN **Johannsson, Gudmundur**; Marin, Per; Lonn, Lars; Ottosson, Malin;  
Stenlof, Kaj; Bjorntorp, Per; Sjostrom, Lars; Bengtsson, Bengt-ake

PA Pharmacia & Upjohn Ab, Swed.; Johannsson, Gudmundur; Marin, Per; Lonn,  
Lars; Ottosson, Malin; Stenlof, Kaj; Bjorntorp, Per; Sjostrom, Lars;

SO PCT Int. Appl., 34 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9738709	A1	19971023	WO 1997-SE601	19970410
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE	CA 2250907	AA	19971023	CA 1997-2250907	19970410
	AU 9724190	A1	19971107	AU 1997-24190	19970410
	EP 935469	A1	19990818	EP 1997-919856	19970410
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO				
PRAI	SE 1996-1397		19960412		
	WO 1997-SE601		19970410		

L7 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2000 ACS

AN 1997:179023 CAPLUS

DN 126:272527

TI **Growth hormone** treatment of abdominally obese men  
reduces abdominal fat mass, improves glucose and lipoprotein metabolism,  
and reduces diastolic blood pressure

AU **Johannsson, Gudmundur**; Maarin, Per; Loenn, Lars; Ottosson,  
Malin; Stenloef, Kaj; Bjorntorp, Per; Sjoestroem, Lars; Bengtsson,  
Bengt-aake

CS Res. Center Endocrinology & Metabolism, Goeteborg, S-413 45, Swed.

SO J. Clin. Endocrinol. Metab. (1997), 82(3), 727-734

CODEN: JCEMAZ; ISSN: 0021-972X

PB Endocrine Society

DT Journal

LA English

L7 ANSWER 6 OF 8 BIOSIS COPYRIGHT 2000 BIOSIS

AN 2000:5388 BIOSIS

DN PREV200000005388

TI **Growth hormone** and the metabolic syndrome.

AU **Johannsson, G.**; Bengtsson, B.-A. (1)

CS (1) Research Centre for Endocrinology and Metabolism, Sahlgrenska  
University Hospital, Goteborg Sweden

SO Journal of Endocrinological Investigation, (1999) Vol. 22, No. 5 SUPPL.,  
pp. 41-46.

ISSN: 0391-4097.

DT General Review

LA English

SL English

L7 ANSWER 7 OF 8 BIOSIS COPYRIGHT 2000 BIOSIS

AN 1997:170525 BIOSIS

DN PREV199799477128

TI **Growth hormone** treatment of abdominally obese men  
 reduces abdominal fat mass, improves glucose and lipoprotein metabolism,  
 and reduces diastolic blood pressure.  
 AU **Johannsson, Gudmundur (1)**; Marin, Per; Lonn, Lars; Ottosson,  
 Malin; Stenlof, Kaj; Bjorntorp, Per; Sjostrom, Lars; Bengtsson, Bengt-Ake  
 CS (1) Research Center Endocrinol. Metabolism, Sahlgrenska Univ. Hosp.,  
 S-413 45 Goteborg Sweden  
 SO Journal of Clinical Endocrinology & Metabolism, (1997) Vol. 82, No. 3,  
 PP. 727-734.  
 ISSN: 0021-972X.  
 DT Article  
 LA English  
 L7 ANSWER 8 OF 8 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.  
 AN 97075322 EMBASE  
 DN 1997075322  
 TI **Growth hormone** treatment of abdominally obese men  
 reduces abdominal fat mass, improves glucose and lipoprotein metabolism,  
 and reduces diastolic blood pressure.  
 AU **Johannsson G.**; Marin P.; Lonn L.; Ottosson M.; Stenlof K.;  
 Bjorntorp P.; Sjostrom L.; Bengtsson B.-A.  
 CS Dr. G. Johannsson, Res. Ctr. Endocrinology/Metabolism, Sahlgrenska  
 University Hospital, S-413 45 Goteborg, Sweden.  
 Gudmundur.Johannsson@ss.gu.se  
 SO Journal of Clinical Endocrinology and Metabolism, (1997) 82/3 (727-734).  
 Refs: 50  
 ISSN: 0021-972X CODEN: JCEMAZ  
 CY United States  
 DT Journal; Article  
 FS 003 Endocrinology  
 006 Internal Medicine  
 037 Drug Literature Index  
 038 Adverse Reactions Titles  
 LA English  
 SL English

=> d his

(FILE 'HOME' ENTERED AT 08:44:56 ON 04 JAN 2000)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE' ENTERED AT 08:45:36 ON 04 JAN 2000  
 E JOHANSSON G/AU

L1 81 S E3  
 L2 45 S E4  
 L3 119 S (L1 OR L2) AND (GH OR (GROWTH AND HORMONE))  
 L4 31070 S INSULIN AND SENSITIVITY  
 L5 13 S L3 AND L4  
 L6 44565 S INSULIN AND RESISTANCE  
 L7 8 S L5 AND L6

=> d his

(FILE 'USPAT' ENTERED AT 08:40:27 ON 08 MAR 1999)  
L1 1 S 5736515/PN  
L2 1 S INSULIN AND L1  
L3 0 S INSULIN(3A) SENSITIV? AND L1  
L4 11510 S ABDOMINAL OR VISCERAL(3A) OBESITY  
L5 0 S L4 AND L1  
L6 0 S NON(3A) INSULIN(3A) DEPEND? AND L1  
L7 3216 S DIABETES AND MELLITUS  
L8 0 S L7 AND L1

=> d 12 kwic

US PAT NO: 5,736,515 [IMAGE AVAILABLE] L2: 1 of 1

ABSTRACT:

A . . . treatment of a patient for obtaining an increased concentration of a factor selected from the group consisting of growth hormone, insulin-like growth factor (IGF-I) and IGFBP-3 in cerebrospinal fluid by administration of growth hormone or analogues thereof to a patient in. . .

SUMMARY:

BSUM(23)

Twenty . . . 30-65 years, who previously had been investigated as in-patients at the Division of Endocrinology because of adult-onset pituitary insufficiency after insulin induced hypoglycaemia, all patients had serum GH concentration below 5 mU/L were asked to participate in the study. All patients. . .

SUMMARY:

BSUM(42)

Insulin-like growth factor 1 (IGF-I) levels in plasma were determined with a RIA kit from Nichols Institute, Wijehe, The Netherlands. The. . .

SUMMARY:

BSUM(44)

Insulin-like growth factor binding protein-3 (IGFBP-3) levels in plasma was determined with a KIA kit from Nichols Institute, Wijehe, The Netherlands. . .

SUMMARY:

BSUM(75)

TABLE 2

Measurements of GH concentration in serum(s) and the cerebrospinal

fluid (CSF), urinary GH, **insulin**-like growth factor I (IGF-I) in plasma, IGF binding protein-3 (IGFBP-3) in plasma and in CSF in patients with Growth Hormone. . . .

DETDESC:

DETD(1)

In the doubleblind placebo-controlled trial we have thus studied the effects on endogenous opioid peptides, neuropeptides, monoamine metabolites, growth hormone and **insulin**-like growth factor binding protein-3 (IGFBP-3) in the cerebrospinal fluid during one month of treatment with recombinant human growth hormone in. . . .

DETDESC:

DETD(13)

6b. Sara VR et al. Evidence for the presence of specific receptors for **insulin**-like growth factors I (IGF-I) and II (IGF-H) and **insulin** throughout the adult human brain. Neurosci Lett 1982;34:39-44.

DETDESC:

DETD(39)

32. . . . S E, Pham H M, Wilson K F, Liu F, Guidice L C, Rosenfeld R G. Measurement and characterization of **insulin**-like growth factor binding protein-3 in human biological fluids: discrepancies between radioimmunoassay and ligand blotting. Endocrinology 1992;131:3051-60.

CLAIMS:

CLMS(1)

We . . . .

treatment of a patient for obtaining an increased concentration of a factor selected from the group consisting of growth hormone, **insulin**-like growth factor-I(IGF-I) and IGFBP-3 in cerebrospinal fluid by administration of growth hormone or analogues thereof to a patient in need. . . .

## PALM INTRANET

Day : Monday  
Date: 3/ 8/1999  
Time: 08:14:38

## Inventor Name Search Result

Your Search was:

Last Name = JOHANNSSON  
First Name = GUDMUNDUR

Serial#	Patent#	Status	Date Filed	Title	Inventor Name
08857245	Not Issued	169	05/16/1997	USE OF GROWTH HORMONE	JOHANNSSON , GUDMUNDUR
09050366	Not Issued	71	03/31/1998	USE OF GROWTH HORMONE	JOHANNSSON , GUDMUNDUR
60017822	Not Issued	2	05/17/1996	USE OF GROWTH HORMONE	JOHANNSSON , GUDMUNDUR
29100206	Not Issued	2	02/05/1999	CONDOM	JOHANNSSON , GUDMUNDUR SIGURDUR

Inventor Search Completed: No more records to search.

Search Another:  
Inventor

Last Name

JOHANNSSON

First Name

GUDMUNDUR

(To Go BACK Use BACK Button on Your BROWSER Tool Bar)

Back to || [PALM](#) || [ASSIGNMENT](#) || [OASIS](#) || [Home Page](#)

**PALM INTRANET**Day : Monday  
Date: 3/ 8/1999  
Time: 08:15:25**Inventor Name Search Result**

Your Search was:

Last Name = MARIN

First Name = PER

Serial#	Patent#	Status	Date Filed	Title	Inventor Name
08115040	Not Issued	161	09/01/1993	NEW MEDICAL USE	MARIN , PER
08776983	5849740	150	02/06/1997	METHODS FOR USING KETOCONAZOLE AND RELATED SUBSTANCES IN MEDICAMENTS	MARIN , PER
08952638	Not Issued	41	02/26/1998	PREPARATION FOR DIAGNOSTIC OF THE METABOLIC SYNDROME AND DISEASES	MARIN , PER
09050366	Not Issued	71	03/31/1998	USE OF GROWTH HORMONE	MARIN , PER
09211282	Not Issued	30	12/14/1998	USE OF KETOCONAZOLE AND RELATED SUBSTANCES IN MEDICAMENTS FOR	MARIN , PER
60017822	Not Issued	2	05/17/1996	USE OF GROWTH HORMONE	MARIN , PER

Inventor Search Completed: No more records to search.

Search Another:  
Inventor

Last Name

MARIN

First Name

PER

Search

(To Go BACK Use BACK Button on Your BROWSER Tool Bar)

Back to || [PALM](#) || [ASSIGNMENT](#) || [OASIS](#) || [Home Page](#)

Day : Monday  
Date: 3/ 8/1999  
Time: 08:18:03

 **PALM INTRANET****Inventor Name Search Result**

Your Search was:

Last Name = LONN

First Name = LARS

Serial#	Patent#	Status	Date Filed	Title	Inventor Name
09050366	Not Issued	71	03/31/1998	USE OF GROWTH HORMONE	LONN , LARS
60017822	Not Issued	2	05/17/1996	USE OF GROWTH HORMONE	LONN , LARS

**Inventor Search Completed: No more records to search.**

**Search Another:**  
**Inventor**

Last Name

LONN

First Name

LARS

(To Go BACK Use BACK Button on Your BROWSER Tool Bar)

Back to || [PALM](#) || [ASSIGNMENT](#) || [OASIS](#) || Home Page

Day : Monday  
Date: 3/ 8/1999  
Time: 08:20:10

**PALM INTRANET****Inventor Name Search Result**

Your Search was:

Last Name = STENLOF

First Name = KAJ

Serial#	Patent#	Status	Date Filed	Title	Inventor Name
09050366	Not Issued	71	03/31/1998	USE OF GROWTH HORMONE	STENLOF , KAJ
60017822	Not Issued	2	05/17/1996	USE OF GROWTH HORMONE	STENLOF , KAJ

**Inventor Search Completed: No more records to search.**

**Search Another:  
Inventor**

Last Name

STENLOF

First Name

KAJ

(To Go BACK Use BACK Button on Your BROWSER Tool Bar)

Back to || [PALM](#) || [ASSIGNMENT](#) || [OASIS](#) || [Home Page](#)

**PALM INTRANET**

Day : Monday  
Date: 3/ 8/1999  
Time: 08:22:55

**Inventor Name Search Result**

Your Search was:

Last Name = BENGTTSSON

First Name = BENGTT-AKE

Serial#	Patent#	Status	Date Filed	Title	Inventor Name
08602728	5736515	150	05/17/1996	USE OF GROWTH HORMONE FOR INCREASEMENT OF CONCENTRATION OF GH, IGF-I	BENGTTSSON , BENGTT-AKE
09050366	Not Issued	71	03/31/1998	USE OF GROWTH HORMONE	BENGTTSSON , BENGTT-AKE

**Inventor Search Completed: No more records to search.**

<b>Search Another: Inventor</b>	<b>Last Name</b>	<b>First Name</b>
	<input type="text" value="BENGTTSSON"/>	<input type="text" value="BENGTT-AKE"/>
	<input type="button" value="Search"/>	

(To Go BACK Use BACK Button on Your BROWSER Tool Bar)

Back to || [PALM](#) || [ASSIGNMENT](#) || [OASIS](#) || [Home Page](#)

**PALM INTRANET**

Day : Monday  
Date: 3/ 8/1999  
Time: 08:10:54

**Serial Number Information**

Serial Number : 08/857245

Filing Date : 05/16/1997

Examiner Number : 00000

Group Art Unit : 0000

Class/Subclass : 514/.

Date of Abandonment : 04/03/1998

Appeal Number :

Location Date : 10/19/1998

Status : 169 / ABANDONED INCOMPLETE FILE - FILING DATE UNDER RULE 53(B)

Location : 9200/FILES REPOSITORY (FRANCONIA) 924-3199 OR 924-7109

Charge to Location : /

Title of Invention :

**USE OF GROWTH HORMONE**

Patent Number :

Issue Date : 00/00/0000

Application Received : 05/16/1997

Examiner Name : **NOT ASSIGNED**

Attorney Docket Number : 0151/00188

Charge to Name : **NOT ASSIGNED**

Unmatched Petition : NO

Status Date : 09/30/1998

**Serial  
Info**[Contents](#)[Attorney Info](#)[Continuity Data](#)[Foreign Data](#)**Search Another: Serial#** **or Patent#** 

(To Go BACK Use BACK Button on Your BROWSER Tool Bar)

Back to || [PALM](#) || [ASSIGNMENT](#) || [OASIS](#) || Home Page

Day : Monday  
Date: 3/ 8/1999  
Time: 08:11:41

**PALM INTRANET****Content Information for 08/857245**

Num	Type	Date	Code	Contents Description
5	O	09/30/1998	ABNF	ABANDONED INCOMPLETE APPLICATION UNDER RULE 53(B) - FILING FEE PAID
4	O	10/02/1997	INCD	INCOMPLETE APPLICATION UNDER RULE 53(B) - FILING DATE ASSIGNED
3	E	08/14/1997	SCAN	APPLICATION SCANNED AND DISPATCHED FROM PRE-EXAM
2	L	10/06/1997	G02D	LOCATION CHANGE IN PRE-EXAM
1	E	06/25/1997	IEXX	INITIAL EXAM TEAM XX

Serial Info   Contents   Attorney Info   Continuity Data   Foreign Da

Search Another: Serial#  Search or Patent#  Search

(To Go BACK Use BACK Button on Your BROWSER Tool Bar)

Back to || [PALM](#) || [ASSIGNMENT](#) || [OASIS](#) || Home Page

Day : Monday  
Date: 3/ 8/1999  
Time: 08:10:06



# PALM INTRANET

## PALM File Request

(WARNING: Data Security and Confidentiality Restriction Apply)

Employee #74981    Location: 1654    TECH CENTER 1600-ART UNIT 1654

File Requested for Serial# 08/857245

Response: Serial# 08/857245  
A-REQ ACCEPTED

Order Another:    Serial#   or Patent#

(To Go BACK Use BACK Button on Your BROWSER Tool Bar)

Back to || [PALM](#) || [ASSIGNMENT](#) || [OASIS](#) || Home Page